Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
70 participants
INTERVENTIONAL
2010-02-28
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
NCT02790125
An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants
NCT04008992
A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants
NCT04082741
Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
NCT01605994
Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects
NCT02257151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 5 mg, Single dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 2 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 20 mg, Single dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 3 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 60 mg, Single dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 4 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 150 mg, Single dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 5 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 300 mg, Single dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 6 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 600 mg, Single Dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
Arm 7 [14C] BMS-813160
[14C] BMS-813160
Oral Solution, Oral, 150 mg, Single Dose, 1 day
Arm 8 (BMS-813160 or placebo)
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
BMS-813160
Oral Solution, Oral, 1200 mg, Single dose, 1 day
Arm 9 (BMS-813160 or placebo)
BMS-813160
Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-813160
Oral Solution, Oral, 5 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 20 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 60 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 150 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 300 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 600 mg, Single Dose, 1 day
[14C] BMS-813160
Oral Solution, Oral, 150 mg, Single Dose, 1 day
Placebo
Oral Solution, Oral, 0 mg, Single Dose, 1 day
BMS-813160
Oral Solution, Oral, 1200 mg, Single dose, 1 day
BMS-813160
Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Exclusion Criteria
* Organ dysfunction or any clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Covance Clinical Research Unit, Inc.
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV202-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.